Wells Fargo & Company Boosts Crescent Capital BDC (NASDAQ:CCAP) Price Target to $18.00

Crescent Capital BDC (NASDAQ:CCAP - Get Free Report) had its target price increased by equities research analysts at Wells Fargo & Company from $16.50 to $18.00 in a report issued on Monday, Benzinga reports. The firm presently has an "equal weight" rating on the stock. Wells Fargo & Company's target price points to a potential upside of 0.33% from the company's current price.

CCAP has been the topic of several other research reports. Raymond James boosted their price objective on shares of Crescent Capital BDC from $18.00 to $19.00 and gave the stock an "outperform" rating in a research note on Friday. Oppenheimer boosted their price target on Crescent Capital BDC from $18.00 to $19.00 and gave the stock an "outperform" rating in a research report on Friday, February 23rd.

Crescent Capital BDC Stock Down 1.4 %

Shares of CCAP stock traded down $0.25 during midday trading on Monday, reaching $17.94. 156,130 shares of the stock were exchanged, compared to its average volume of 100,642. Crescent Capital BDC has a 1 year low of $13.37 and a 1 year high of $18.20. The firm has a market cap of $664.86 million, a PE ratio of 6.44 and a beta of 0.81. The company's 50 day moving average is $17.24 and its two-hundred day moving average is $16.89. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 1.11.

Crescent Capital BDC (NASDAQ:CCAP - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The company had revenue of $50.00 million for the quarter, compared to analysts' expectations of $47.99 million. Crescent Capital BDC had a return on equity of 11.99% and a net margin of 53.32%. On average, equities research analysts predict that Crescent Capital BDC will post 2.3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James & Associates lifted its position in Crescent Capital BDC by 11.7% in the 3rd quarter. Raymond James & Associates now owns 146,303 shares of the company's stock valued at $2,502,000 after acquiring an additional 15,271 shares in the last quarter. Anchor Investment Management LLC purchased a new stake in shares of Crescent Capital BDC during the fourth quarter valued at $342,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Crescent Capital BDC in the 3rd quarter worth about $240,000. International Assets Investment Management LLC purchased a new position in Crescent Capital BDC in the 4th quarter worth about $1,254,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Crescent Capital BDC in the 4th quarter worth about $843,000. Institutional investors own 49.46% of the company's stock.

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.